HSP90AB1 (Heat Shock Protein 90 Alpha Family Class B Member 1)

This study identified six key genes regulating colorectal tumorigenesis and constructed a high-performance diagnostic model. These findings provide novel insights into the molecular mechanisms underlying the initiation and progression of CRC, and offer potential biomarkers and therapeutic targets for the clinical diagnosis and treatment of CRC.

Our study suggests that 14-3-3β modulates the phosphorylated alterations of the cancer-related proteome. Unveiling the role of the 14-3-3β/Hsp90B pathway in GC CDDP resistance implies it could serve as a potential therapeutic target for treating CDDP-resistant GC patients.

These findings reveal the therapeutic potential of TN against AML through inhibiting the PI3K/AKT axis. With no PI3K/AKT inhibitors targeting AML approved as first-line therapies, TN emerges as a promising candidate for AML treatment, offering a safer natural alternative.

Our integrative analysis demonstrates that no single physiological parameter fully defines the species' thermal limits; however, hemolymph oxygenation and motor activity most closely align with field-based distribution patterns. These results are somewhat consistent with the oxygen- and capacity-limited thermal tolerance (OCLTT) framework but highlight the utility of a multi-parameter approach consistent with the Multiple Performances-Multiple Optima (MPMO) concept.

Additionally, Apoe in microglia and genes related to protein folding in oligodendrocytes are upregulated at late aging stages, while genes involved in myelination are downregulated at early aging stages in oligodendrocyte. Our multiomic atlas underscores the substantial regulatory network changes during aging that may predispose to PD, providing valuable insights for furthering understanding of PD pathogenesis and potential therapeutic targets.

TFR patients exhibited distinct enrichment in complement and coagulation cascades (C3, C4B, F9, F11) and metabolic pathways. Plasma EV proteomes reflect CML clinical status, revealing immune and cytoskeletal alterations associated with treatment response, remission, and resistance, suggesting potential biomarkers for disease monitoring.

Additionally, HSP90B1 might enhance glioma metastasis and resistance to radiotherapy by regulating RhoC expression. This regulatory effect was achieved by the directly binding of HSP90B1 to RhoC, thereby preventing its degradation through the ubiquitin-proteasome pathway.

Finally, through virtual screening and Co-IP, we identified ivermectin as a potent inhibitor of the HSP90AB1-ITGBL1 interaction, and treatment with ivermectin dramatically inhibited OS progression in vivo. In conclusion, we uncover a novel mechanism that promotes OS progression and identify a new candidate drug for the treatment of OS.

Crucially, the HSP90AB1 K265R mutation or pharmacological inhibition of ACOX1 (10,12-tricosadiynoic acid) or TXN (1-methyl-propyl 2-imidazolyl disulfide, PX-12) synergizes with cisplatin to suppress tumor growth in vivo by disrupting redox adaptation. These findings reveal that crotonylation is a hypoxia-sensitive rheostat for TXN-mediated redox control, suggesting that the ACOX1-HSP90AB1-TXN axis is a therapeutic vulnerability in therapy-resistant OSCC.

Subsequent SHAP analysis revealed SRC, HSP90AB1, HSP90AA1 and CDK1 as the key contributors to prognostic prediction, with each being highly expressed in BC and linked to poor clinical prognosis. Notably, among all chemicals screened, Disperse Yellow 3 exhibited the strongest binding affinity to these four key targets, demonstrating the strongest association with BC risk.

Diff-Metabolic cells retained liver-specific functions with favorable prognosis, whereas the other three programs correlated with disease advancement; notably, all four states exhibited differential therapeutic vulnerabilities, including sorafenib resistance...Geneformer-based virtual knockout screening identified HSP90B1 as a convergent dependency, validated by its cancer cell essentiality, HCC overexpression, abundance in treatment-resistant tumors, and association with adverse survival. This integrated atlas establishes a framework for targeting tumor-intrinsic states and microenvironmental dependencies in HCC.

SB may regulate TRP-induced bone metabolism abnormalities in LNCaP cells through the IL-17 signaling pathway as well as five DEPs: p-ERK2, RELA, HSP90B1, GNAI1and GNAI3.